Viridian Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 6, 2026 (with events reported through May 11, 2026), details two significant capital raising transactions completed by Viridian Therapeutics, Inc. The company, a biopharmaceutical firm focused on thyroid eye disease and other pipeline assets, executed a concurrent equity offering and convertible notes offering to strengthen its balance sheet and fund operations.
Key Financial Metrics and Capital Structure
- Equity Offering: Issued 7,352,942 shares of Common Stock at $17.00 per share. Net proceeds were approximately $117.0 million.
- Convertible Notes Offering: Issued $250.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2032 (including full exercise of the $25.0 million over-allotment option). Net proceeds were approximately $242.0 million.
- Total Capital Raised: Approximately $359.0 million in combined net proceeds.
- Debt Terms: Notes bear interest at 1.75% per annum, payable semiannually. Initial conversion price is approximately $24.65 per share (40.5680 shares per $1,000 principal amount).
- Liquidity Impact: The filing does not provide pre-offering cash balances or total debt figures, but the proceeds are designated to repay all outstanding indebtedness under a prior loan agreement with Hercules Capital, Inc.
Material Changes and Use of Proceeds
The primary material change is the significant increase in cash liquidity and the addition of $250.0 million in senior convertible debt. The company intends to use the net proceeds for the following purposes:
- Repayment of all outstanding indebtedness under the Loan and Security Agreement dated April 1, 2022, with Hercules Capital, Inc.
- Funding market expansion studies for its thyroid eye disease franchise.
- Advancing research and development of its earlier pipeline.
- Working capital and general corporate purposes.
Outlook, Risks, and Contingencies
Management views these transactions as critical for funding near-term operational goals and R&D. The filing includes standard forward-looking statements regarding the anticipated use of proceeds and future performance, noting that these are subject to risks and uncertainties.
Key Risks and Contingencies:
- Dilution: Up to 14,705,875 shares of Common Stock may be issued upon conversion of the Notes based on the initial maximum conversion rate, subject to anti-dilution adjustments.
- Redemption and Repurchase: The Notes are redeemable by the company after May 20, 2030, subject to specific stock price conditions. Noteholders have the right to require repurchase upon a "Fundamental Change" (e.g., business combination or delisting).
- Events of Default: Includes payment defaults, failure to file reports, bankruptcy, and certain defaults on other indebtedness exceeding $30 million.
- Special Interest: Failure to file required SEC reports may trigger special interest accruals of 0.25% to 0.50% per annum.
Investor Verification Checklist
- Verify the exact amount of outstanding debt under the Hercules Capital agreement to confirm the full repayment capability.
- Review the "Risk Factors" section in the Company's Form 10-Q for the quarter ended March 31, 2026, for detailed operational and financial risks.
- Monitor the Company's stock price relative to the $24.65 conversion price to assess the likelihood of future conversion and dilution.
- Confirm the status of the over-allotment option exercise (noted as fully exercised in this filing) and the final share count issued.
- Check subsequent filings for the actual cash balance post-closing and the specific allocation of funds to R&D versus debt repayment.